SCHEMBL10150313

SCHEMBL10150313

CC1CCc2nc(-c3ccccc3O)nc(N(C)C)c2C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.42
ALDH1A1 P00352 7/20 0.42
CHEK2 O96017 2/20 0.42
MAPT P10636 4/20 0.39
KMT2A Q03164 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
MEN1 O00255 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 2/20 0.39
MAPK1 P28482 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HSP90AA1 P07900 1/20 0.37
HSD17B10 Q99714 5/20 0.36
HPGD P15428 3/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
USP2 O75604 1/20 0.36
C5AR1 P21730 1/20 0.36
HTT P42858 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL172835 0.90 CHEK2 (0.42) KDM4EALDH1A1CHEK2MAPTKMT2A
SCHEMBL10150303 0.90 CHEK2 (0.42) KDM4EALDH1A1CHEK2MAPTKMT2A
SCHEMBL8299286 0.83 ALDH1A1 (0.46) KDM4EALDH1A1CHEK2KMT2ATDP1
SCHEMBL8299281 0.83 ALDH1A1 (0.49) KDM4EALDH1A1CHEK2KMT2ATDP1
SCHEMBL8297566 0.82 ALDH1A1 (0.48) KDM4EALDH1A1CHEK2KMT2ATDP1
SCHEMBL8299277 0.82 ALDH1A1 (0.48) KDM4EALDH1A1CHEK2KMT2ATDP1
SCHEMBL10150318 0.80 SMAD3 (0.53) KDM4EALDH1A1CHEK2MAPTKMT2A
SCHEMBL10150319 0.79 SMAD3 (0.52) KDM4EALDH1A1CHEK2MAPTKMT2A
SCHEMBL8298128 0.78 HTR2C (0.44) KDM4EALDH1A1CHEK2KMT2ATDP1
SCHEMBL10150324 0.77 ALDH1A1 (0.53) KDM4EALDH1A1CHEK2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 KDM4E 2477/4885ALDH1A1 3086/4885CHEK2 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.